News and Trends 13 Mar 2023 New therapy for prevention and treatment of COVID-19 …currently a strong need for antibodies that work against the newest omicron variants, we think it is useful to rapidly communicate to our scientific colleagues about the discovery that targeting… March 13, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 22 Dec 2021 The Biggest European Biotech News of 2021 …ongoing stock price falls hitting public biotechs globally. December A heavily mutated form of Covid-19 called the omicron variant reared its head, threatening a fresh pandemic wave around the world…. December 22, 2021 - 10 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 14 Oct 2024 Six biomimicry biotech companies harnessing nature’s wisdom to develop breakthrough drug candidates …XVR012, which is made up of two of its other COVID-19 antibody therapies (XVR013m and XVR014), demonstrated potency in neutralizing COVID-19 Omicron variants. ExeVir raised €23 million ($25 million) in… October 14, 2024 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jan 2023 Ascletis phase I COVID trial progressing …Nirmatrelvir, S-217622, PBI-0451 and EDP-235. ASC11 remains potent antiviral activity against various popular Omicron variants such as BA.1 and BA.5. In the animal model with infectious SARS-CoV-2, ASC11 also showed… January 17, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 14 Apr 2023 mRNA vaccines: a promising future …Spikevax vaccine compared to those given a dummy injection. As of March 2023, more than 250 million people in the U.S. have been dosed. The vaccine’s efficacy for the Omicron… April 14, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 24 Nov 2022 FDA gives IND approval for Ascletis Covid drug …infectious SARS-CoV-2, ASC11 demonstrated much higher potency against SARS-CoV-2 than other 3CLpro inhibitors including Nirmatrelvir, S-217622, PBI-0451 and EDP-235. ASC11 remains potent antiviral activity against various popular Omicron variants such… November 24, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email